AI assistant
Sending…
ClearPoint Neuro, Inc. — Regulatory Filings 2026
Feb 9, 2026
32641_rf_2026-02-09_e31ba7b4-363d-4073-8dc9-43500041ff1d.zip
Regulatory Filings
Open in viewerOpens in your device viewer
Exhibit 107
Calculation of Filing Fee Table
FORM S-8
(Form Type)
ClearPoint Neuro, Inc.
(Exact Name of Registrant as Specified in its Charter)
Table 1: Newly Registered Securities
| Security Type | Security Class Title | Fee Calculation Rule | Amount Registered (1) | Proposed Maximum Offering Price Per Share | Maximum Aggregate Offering Price | Fee Rate | Amount of Registration Fee |
|---|---|---|---|---|---|---|---|
| Equity | Common Stock, par value $0.01 per share | Other | 405,000 (2) | $ 3.11 (3) | $ 1,259,550 (3) | $ 0.0001381 | $ 173.94 |
| Total Offering Amounts | $ 173.94 | ||||||
| Total Fees Previously Paid | — | ||||||
| Total Fee Offsets | — | ||||||
| Net Fee Due | $ 173.94 |
| (1) | Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement shall also cover an indeterminate number of additional shares of common stock, $0.01 par value per share (the “Common Stock”), of ClearPoint Neuro, Inc. (the “Company”), which become issuable under (i) the Non-Qualified Stock Option Agreement, dated September 29, 2020, by and between the Company and Danilo D’Alessandro or (ii) the Non-Qualified Stock Option Agreement, dated November 7, 2017, by and between the Company and Joseph Michael Burnett, by reason of any stock splits, stock dividends, reorganizations, mergers, consolidations, recapitalizations or other similar transactions. |
|---|---|
| (2) | Represents 405,000 shares of Common Stock to be issued upon the exercise of outstanding stock options. |
| (3) | The proposed maximum offering price per share and maximum aggregate offering price are based upon the weighted average exercise price of the outstanding options, which is estimated solely for the purposes of calculating the registration fee under Rule 457(h) under the Securities Act. |
| SMRH:4929-5059-0349.5 |
|---|
| 80VE-404774 |
More from ClearPoint Neuro, Inc.
Regulatory Filings
2026
May 21
Regulatory Filings
2026
May 20
Interim / Quarterly Report
2026
May 13
Annual Report
2026
Apr 23
Major Shareholding Notification
2026
Mar 26
Director's Dealing
2026
Mar 20
Director's Dealing
2026
Feb 26
Director's Dealing
2026
Feb 19
Director's Dealing
2026
Feb 19
Director's Dealing
2026
Feb 19